US › Healthcare

OmniAb Inc. (OABI)

US · Healthcare · Biotechnology

$4.44+2.07%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$13.4M

Revenue YoY

+244.2%

Net profit

$-5.9M

EPS

$-0.05

EPS estimate

$-0.11

Net margin

-43.7%

EPS came in at -0.05 against a street estimate of -0.11 — a beat of 54.5%.

Key statistics

Market cap

$591.7M

Forward P/E

0.0

P/B

2.28

Book value

$1.79

EPS (TTM)

$-0.36

52-week high

$5.43

52-week low

$1.30

50-day MA

$3.12

200-day MA

$2.21

Beta

1.42

Analyst view

Analysts rate OmniAb Inc. a strong buy (8 buy, 0 hold, 0 sell out of 8) with an average price target of $8.40.

Shareholding

Insiders

15.28%

Institutions

52.77%

Largest institutional holders

Fund	Stake
Whitefort Capital Management, LP.	7.05%
BlackRock Inc	5.58%
Nomura Holdings Inc	3.46%
Cadian Capital Management LP	2.90%
Vanguard Capital Management, LLC	2.75%
Geode Capital Management, LLC	2.01%
Rice Hall James & Associates, LLC	1.80%
Private Management Group Inc	1.67%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for OmniAb Inc. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.